Get the Stockscreener App
1.15
0.86%
-0.01
Sonoma Pharmaceuticals Inc stock is traded at $1.15, with a volume of 31,299.
It is down -0.86% in the last 24 hours and down -10.16% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$1.16
Open:
$1.15
24h Volume:
31,299
Relative Volume:
0.76
Market Cap:
$5.51M
Revenue:
$19.53M
Net Income/Loss:
$-3.18M
P/E Ratio:
-0.6091
EPS:
-1.888
Net Cash Flow:
$-4.13M
1W Performance:
-0.86%
1M Performance:
-10.16%
6M Performance:
-48.66%
1Y Performance:
-71.39%
1-Day Range:
$1.12
$1.21
1-Week Range:
$1.12
$1.29
52-Week Range:
$0.8501
$4.25
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
1.15 | 5.51M | 19.53M | -3.18M | -4.13M | -1.888 |
TAK
Takeda Pharmaceutical Co Adr
|
19.45 | 62.13B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.11 | 47.95B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.94 | 43.71B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.42 | 32.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.51 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Reviva Pharmaceuticals Holdings (OTCPK:RVPH)Stock Analysis - Simply Wall Street
Kazia Therapeutics Limited (KZIA) stock price, news, quote and history - Yahoo Finance Singapore
Williams-Sonoma CFO Jeffrey Howie Sells 3,045 Shares - Yahoo Finance
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.32SuperTrend - siam.in
Williams-Sonoma, Inc. declares quarterly cash dividend - Yahoo Finance
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.32Stock Surge Alerts - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Ticks Up to $1.31, Holding Above Key SupportHagopian Line - siam.in
Sonoma Pharmaceuticals (SNOA) Ticks Up to $1.31, Holding Above Key SupportBollinger Squeeze - careplusvn.com
Sonoma Pharmaceuticals (SNOA) Ticks Up to $1.31, Holding Above Key SupportNHNL Ratio - dars.gov.et
Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA? - StockInvest.us
Sonoma (SNOA) Market: Holds Near $1.34 in the Available Record; Current Setup: the Session Ends Within the Reported Technical Boundaries on the DayIV Contraction - vinanet.vn
Sonoma (SNOA) Market: Loses 0.75% to Close at $1.33; Key Range: Support at $1.26 and Resistance at $1.40 Frame the Range on the DayMid Cap Momentum - vinanet.vn
Sonoma (SNOA) Market: Loses 0.75% to Close at $1.33; Key Range: Support at $1.26 and Resistance at $1.40 Frame the Range on the DayPut Dominated - vinanet.vn
Sonoma (SNOA) Market: Loses 0.75% to Close at $1.33; Key Range: Support at $1.26 and Resistance at $1.40 Frame the Range on the DayOverbought Signal Alerts - siam.in
Sonoma (SNOA) Shares: Holds Near $1.34 at the Close; Technical View: the Session Ends Within the Reported Technical Boundaries in Latest TradingBear Flag - vinanet.vn
Sonoma (SNOA) Shares: Holds Near $1.34 at the Close; Technical View: the Session Ends Within the Reported Technical Boundaries in Latest TradingPrice Surge Stocks - siam.in
Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting - TipRanks
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum - Investing.com
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com UK
Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Canada
Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com India
Price to earnings forward of Sonoma Pharmaceuticals, Inc. – SWB:O8Z - TradingView
WEBTOON (WBTN) Earnings Brief: EPS Clears the Reported Estimate in the Latest Session; Trading Response: Shares Finish 1.90% Down on the DayEarnings Decline Risk - www.dars.gov.et
Pagaya Technologies Warrants (PGYWW) Drop 7.02% to $0.03 as Trading Remains Pinned at Penny LevelETF Outflow Streak - dars.gov.et
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 - Investing.com
Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive - TradingKey
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Q1 revenue rises on US growth - TradingView
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Bay to Bay News
BRIEF-Sonoma Pharmaceuticals Q1 Operating Expenses USD 2.6 Million - TradingView
Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan
Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary - TradingView
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - TradingView
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - ACCESS Newswire
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Yahoo Finance
Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsStop Loss Guidance - dars.gov.et
SNOA Q1'26 Earnings: EPS estimate is (0.30) USD - TradingView
Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsBreak of Structure - vinanet.vn
SNOA Q2 2026 Earnings: Narrow EPS Miss Weighs on SharesROE Trend Analysis - vinanet.vn
SNOA Q2 2026 Earnings: Narrow EPS Miss Weighs on SharesEarnings Revision Upgrade - dars.gov.et
Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com Nigeria
Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (SNOA) Hovers Near Support as Slight Decline ContinuesEarnings Miss Risk - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Hovers Near Support as Slight Decline ContinuesRVOL Breakout - vinanet.vn
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.35%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):